AbCellera Biologics Inc.
ABCL
Rank in Stocks
#4244
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Share Price
$11.61
Market Cap
$3.76B
Change (1 day)
-2.68%
Change (1 year)
98.12%
Country
CA
Trade AbCellera Biologics Inc. (ABCL)
Category
Healthcare
Number of shares outstanding for AbCellera Biologics Inc. (ABCL)
Number of shares outstanding as of June 2026: 305.56M
According to AbCellera Biologics Inc. latest financial reports and stock price the company's current number of shares outstanding is 305.56M. At the end of December 2023 the company had 289.17M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for AbCellera Biologics Inc. (ABCL) from 2018 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 305.56M | 3.82% |
| 2024 | 294.33M | 1.78% |
| 2023 | 289.17M | 1.44% |
| 2022 | 285.06M | 3.37% |
| 2021 | 275.76M | 2.96% |
| 2020 | 267.82M | 24.33% |
| 2019 | 215.41M | 42.60% |
| 2018 | 151.06M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | -16.91% |
US
|
|
| 396.00M | 29.60% |
US
|
|
| 478.91M | 56.73% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -79.65% |
NL
|
